Indian markets are down, presenting a buying opportunity for long-term investors. Vikas Khemani of Carnelian Asset Management sees potentia...

India’s healthcare and life sciences sector has surpassed its Covid-era fundraising peak, with inflows crossing Rs 62,432 crore, says Equir...

India’s market is entering a new earnings-led cycle, says InCred AM’s Aditya Sood. With Nifty earnings expected to grow 10–12% and midcaps ...

Indian healthcare is entering a new growth cycle, with hospitals and CDMO players expected to deliver strong 20% EBITDA CAGR, while large g...

Sudip Bandyopadhyay advises caution in pharma due to US tariff uncertainties, recommending domestic-focused companies like Mankind Pharma f...

Sun Pharma faces potential impact from the US 100% tariff on patented drugs, which could reduce FY26–27 earnings by 8–10%. Generic drugs re...

Shree Ramkrishna Exports, a prominent natural diamond company, has ventured into the pharmaceutical industry with the launch of Kriam Pharm...

Macquarie is optimistic about Indian pharma and CDMO companies, predicting significant upside potential due to recent market corrections an...

Indian CDMOs are strategically expanding through acquisitions in the US and Europe, driven by global pharma's nearshoring trend and a desir...

Exporters can pass on cost increases to consumers, and the favourable USD/INR exchange rate and increased outsourcing opportunities are exp...

India's CDMO market is set to grow from USD 7 billion to USD 14 billion by 2028. This growth is driven by its strong stance in API manufact...

Shares of Syngene International dropped 5.7%, Piramal Pharma fell 4.2%, Lauras Labs and Neuland Laboratories declined 3% and Divi's Laborat...

OneSource Specialty Pharma, an associate of Strides Pharma, secured Rs. 801 crore from investors including HBM Healthcare Investments and W...

Suven will initially acquire a 67.5% equity stake of Sapala subject to customary working capital and net debt adjustments, the remaining st...

China has for nearly 20 years been the preferred location for a range of pharmaceutical research and manufacturing services due to the low ...

Piramal Pharma chairperson Nandini Piramal in an interview to ET said the company is aiming for mid-teen revenue growth and a meaningful im...

“There is always a possibility of policy driven action in terms of lowering rates or putting a ceiling on rates, etc so that's something th...